Blog & Resources Camargo Blog October 26th, 2009

FDA Reaffirms 5-year Exclusivity for a Prodrug

FDA has reaffirmed its prior assignment of 5 years exclusivity to Vyvance (lisdexamfetamine dimesylate). When Vyvance was approved in 2007, this prodrug of dextramphetamine was given NCE status with a 5 year exclusivity. With this exclusivity, the FDA may not accept an ANDA before the exclusivity expires unless a paragraph IV is filed, in which case the ANDA may be filed 1 year prior to the expiration of the exclusivity.

Actavis filed an ANDA on 1/28/2009 with a paragraph IV certification. FDA refused to file this ANDA on the grounds that it was too early. Actavis sued the FDA in the D.C. District court. (see Actavis complaint re: Vyvance ) This complaint argues that FDA made an error of law in granting the NCE status.

FDA opened a public docket in April 2009. Last week, FDA confirmed (fda-2009-n-0184-00341) that lisdexamfetamine is entitled to NCE exclusivity. The FDA stated:

Lisdexamfetamine is a prodrug that is metabolically converted to produce dextroamphetamine, which is responsible for the drug’s activity. Under FDA’s regulation at 21 CFR § 314.108, a non-ester covalently bonded molecule is considered the active moiety ofa drug and, if not previously approved, it will be considered a new chemical entity entitled to 5 years of exclusivity. A non-ester that requires metabolic conversion to produce a previously approved active moiety is considered a new chemical entity. Because lisdexamfetamine is a non-ester covalently bonded molecule, and because it requires metabolic conversion to produce dextroamphetamine, lisdexamfetamine is a new chemical entity and is thus entitled to 5 years of exclusivity.

Camargo has worked on a number of prodrugs and we have found that FDA is consistent in how it makes the determination.

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
2505 Meridian Parkway
Suite 150
Durham NC, 27713
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights